Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Group Activities

Publications (Wallenberg Affiliation)

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Schöll M, Dansereau C, Villeneuve S, van der Flier WM, Scheltens P, Bellec P, Evans AC, Hansson O, Ossenkoppele R; Alzheimer's Disease Neuroimaging Initiative; Swedish BioFINDER Study. Hum Brain Mapp. 2019 Feb 1;40(2):638-651
DOI: 10.1002/hbm.24401

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease. Mattsson N, Insel PS, Donohue M, Jögi J, Ossenkoppele R, Olsson T, Schöll M, Smith R, Hansson O. Alzheimers Dement. 2019 Jan 24. pii: S1552-5260(18)33605-7.
DOI: 10.1016/j.jalz.2018.12.001.

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A. Acta Neuropathol Commun. 2019 Jan 9;7(1):5.
DOI: 10.1186/s40478-018-0649-3.

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Westwood S, Baird AL, Hye A, Ashton NJ, Nevado-Holgado AJ, Anand SN, Liu B, Newby D, Bazenet C, Kiddle SJ, Ward M, Newton B, Desai K, Tan Hehir C, Zanette M, Galimberti D, Parnetti L, Lleó A, Baker S, Narayan VA, van der Flier WM, Scheltens P, Teunissen CE, Visser PJ, Lovestone S. Front Aging Neurosci. 2018 Dec 11;10:409.
DOI: 10.3389/fnagi.2018.00409

Biomarkers for tau pathology. Schöll M, Maass A, Mattsson N, Ashton NJ, Blennow K, Zetterberg H, Jagust W. Mol Cell Neurosci. 2018 Dec 7. pii: S1044-7431(18)30233-1
DOI: 10.1016/j.mcn.2018.12.001

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Mattsson N, Eriksson O, Lindberg O, Schöll M, Lampinen B, Nilsson M, Insel PS, Lautner R, Strandberg O, van Westen D, Zetterberg H, Blennow K, Palmqvist S, Stomrud E, Hansson O. Neurobiol Aging. 2018 Nov;71:81-90.
DOI: 10.1016/j.neurobiolaging.2018.07.003

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. Gonzales MM, Insel PS, Nelson C, Tosun D, Schöll M, Mattsson N, Sacuiu S, Bickford D, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative. Int J Geriatr Psychiatry. 2018 Oct;33(10):1305-1311.
DOI: 10.1002/gps.4926

No association of salivary total tau concentration with Alzheimer's disease. Ashton NJ, Ide M, Schöll M, Blennow K, Lovestone S, Hye A, Zetterberg H. Neurobiol Aging. 2018 Oct;70:125-127.
DOI: 10.1016/j.neurobiolaging.2018.06.014

Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition. Thal DR, Beach TG, Zanette M, Lilja J, Heurling K, Chakrabarty A, Ismail A, Farrar G, Buckley C, Smith APL Acta Neuropathol. 2018 Oct;136(4):557-567.
DOI: 10.1007/s00401-018-1897-9

Discriminative accuracy of [18f] flortaucipir positron emission tomography for alzheimer disease vs other neurodegenerative disorders. Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Schöll M, Strandberg O, Palmqvist S, Mattsson N, Janelidze S, Santillo A, Ohlsson T, Jögi J, Tsai R, La Joie R, Kramer J, Boxer AL, Gorno-Tempini ML, Miller BL, Choi JY, Ryu YH, Lyoo CH, Hansson O. JAMA. 2018 Sep 18;320(11):1151-1162.
DOI: 10.1001/jama.2018.12917

Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. Grothe MJ, Sepulcre J, Gonzalez-Escamilla G, Jelistratova I, Schöll M, Hansson O, Teipel SJ; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2018 Sep 1;141(9):2755-2771
DOI: 10.1093/brain/awy189.

In vivo Detection of Alzheimer's Disease. Leuzy A, Heurling K, Ashton NJ, Schöll M, Zimmer ER.
Yale J Biol Med. 2018 Sep 21;91(3):291-300
PMCID: PMC6153625

Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, Schöll M. J Cereb Blood Flow Metab. 2018 Aug 3:27
DOI: 10.1177/0271678X18791430

Altered Glucose Uptake in Muscle, Visceral Adipose Tissue, and Brain Predict Whole-Body Insulin Resistance and may Contribute to the Development of Type 2 Diabetes: A Combined PET/MR Study. Boersma GJ, Johansson E, Pereira MJ, Heurling K, Skrtic S, Lau J, Katsogiannos P, Panagiotou G, Lubberink M, Kullberg J, Ahlström H, Eriksson JW. Horm Metab Res. 2018 Aug;50(8):627-639
DOI: 10.1055/a-0831-3620

Update on biomarkers for amyloid pathology in Alzheimer's disease. Ashton NJ, Schöll M, Heurling K, Gkanatsiou E, Portelius E, Höglund K, Brinkmalm G, Hye A, Blennow K, Zetterberg H. Biomark Med. 2018 Jul;12(7):799-812
DOI: 10.2217/bmm-2017-0433

Shape-aware label fusion for multi-atlas frameworks. Jennifer Alvén, Fredrik Kahl, Matilda Landgren, Viktor Larsson, Johannes Ulén, Olof Enqvist.
https://doi.org/10.1016/j.patrec.2018.07.008

International Presentations

Michael Schöll

Human Amyloid Imaging, Miami (2019-01-16): Head-to-head comparison of [18F]Flortaucipir and [18F]RO948 tau PET ligands

German Centre for Neurodegenerative diseases (DZNE) Magdeburg (2018-12-17): Head-to-head comparison of [18F]Flortaucipir and [18F]RO948 tau PET ligands

Duke-NUS (2018-11-12): Update on what we believe is tau imaging

Stanford University (2018-09-03): Update on what we believe is tau imaging

Nicholas Ashton

The German Association of Psychiatry, Psychotherapy and Psychosomatics (DGPPN) Berlin (2018-12-01): Blood biomarkers for neurodegeneration; an update.

Page Manager: Mattias Lindgren|Last update: 4/18/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?